Siltuximab
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Siltuximab: From No Registered Indication to Extracutaneous Mastocytoma (Predicted)
One-Sentence Summary
Siltuximab does not currently hold a marketing license or documented approved indication in this jurisdiction, and it is known pharmacologically as a chimeric anti-IL-6 monoclonal antibody. The TxGNN model predicts it may be effective for Extracutaneous Mastocytoma, but this prediction is currently supported by 0 clinical trials and 0 publications, making it a model-only hypothesis at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — drug is not marketed in this jurisdiction; no license/indication text on file |
| Predicted New Indication | Extracutaneous Mastocytoma |
| TxGNN Prediction Score | 99.64% |
| Evidence Level | L5 |
| Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on information contained in this evidence pack, siltuximab is a chimeric (human-murine) anti-interleukin-6 (IL-6) monoclonal antibody administered by intravenous infusion.
The model’s own rationale notes that IL-6 expression has occasionally been observed in mastocytoma lesions in association with local inflammatory activity. However, there is no direct evidence that IL-6 acts as a key driver pathway for tumor growth in extracutaneous mastocytoma — the mechanistic link is described as weak and inferential rather than established. This prediction should therefore be treated as a hypothesis-generating signal from the knowledge graph rather than a mechanistically validated candidate.
It is also worth noting that among the eight indications TxGNN predicted for siltuximab, Kaposi’s sarcoma (rank 5) carries comparatively stronger mechanistic plausibility — IL-6 is implicated in HHV-8-driven pathology and in HHV-8-associated multicentric Castleman’s disease, which frequently co-occurs with Kaposi’s sarcoma — and reached evidence level L4 with at least indirect literature support. This may be a more productive direction for follow-up than the top-ranked mastocytoma prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Market Information
This drug is not currently marketed in this jurisdiction. No license records, product names, dosage forms, or approved indication text are on file.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA warning/contraindication data and drug interaction data are currently unavailable and are flagged as a blocking data gap (DG001) — this must be resolved before any safety pre-assessment (S1) can proceed for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (extracutaneous mastocytoma) has no clinical trial or literature support and rests on an explicitly weak, inferential mechanistic link (L5 — model prediction only). Combined with the absence of local market authorization and missing safety labeling data, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA (or equivalent local regulator) package insert — warnings and contraindications (blocking gap, DG001)
- Confirmed mechanism of action data from DrugBank or primary literature (DG002)
- Preclinical or case-level evidence directly evaluating IL-6 blockade in mastocytoma
- Consider evaluating the rank-5 candidate (Kaposi’s sarcoma), which currently has a stronger mechanistic rationale (HHV-8/IL-6 axis) and reached evidence level L4, as a higher-priority research question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.